National Health Insurance Directory Adjustments To the Good Of These Pharmaceutical Companies (With List)

A new round of medical insurance catalog adjustment is under way, according to the pharmaceutical Rubik's Cube PharmaGo data, according to the number of varieties and exclusive variety dimension, Ha Pharmaceuticals, Sunflower Pharmaceuticals, Hyundai Pharmaceuticals, China Resources Shuanghe, Step Pharmaceuticals, Howson Pharmaceuticals, Hengrui Pharmaceuticals, Stone Pharmaceuticals Group and other enterprises or benefit from a new round of medical insurance catalog adjustment.
(September 18), the State Health Insurance Administration announced the "2020 National Health Insurance Drug Catalog Adjustment through formal examination of the list of declared drugs" (hereinafter referred to as the "List").
, 728 drugs passed the formal review, according to Seber blue combing.
addition, there are 23 negotiated drugs in the catalogue that need to recalculate medicare payment standards and significant changes in adaptive disorders, meaning that about 751 varieties have passed formal reviews this time.
notice, the National Health Insurance Administration noted that subjects and individuals who have an opinion on the List can give feedback to them by 17:00 on 25 September.
the work arrangements adjusted according to the new round of health insurance catalogue: 1, preparation phase (July-August 2020); October); 4, Negotiation and Bidding Phase (October-November 2020); Announcement Results Phase (November-December 2020) means that after the publication period of the List, the adjustment of the health insurance catalogue will enter the expert review phase. Data from
Pharmaceutical Rubik's Cube show that 42 pharmaceutical companies, including Ha Pharmaceuticals, Sunflower Pharmaceuticals, Hyundai Pharmaceuticals, China Resources Shuanghe, Colum Pharmaceuticals, Stone Pharmaceuticals Group, Guang Pharmaceutical Group, Furen Pharmaceuticals, Correctional Pharmaceuticals, Taiji Group, China Resources 39, etc., have reviewed the number of drugs in the form of adjustment of the national medical insurance catalogue.
(Photo Source: Pharmaceutical Rubik's Cube) Of these, the number of drugs reviewed by Kazakhstan Pharmaceuticals through form reached 95, the number of drugs reviewed by Sunflower Pharmaceuticals through form reached 84, the number of drugs reviewed by modern pharmaceutical companies through form reached 83, and the number of drugs reviewed by China Resources Shuanghe through form reached 79.
in this list, GM Kangli, LuoXin Pharmaceuticals, Tiansheng Pharmaceuticals, Tian Zhi Pharmaceuticals, Chenxin Pharmaceuticals five pharmaceutical companies through the form of the least number of drugs reviewed, also 25.
, the above-mentioned pharmaceutical companies are expected to pass the quantitative advantage, in a new round of national health insurance directory adjustment, to seek good results.
In addition, step pharmaceutical, Howson Pharmaceuticals, Peking University Pharmaceuticals, Hengrui Pharmaceuticals, Guizhou Bailing, Renfu Pharmaceuticals, Shi Pharmaceutical Group, Geopharmaceuticals and other 38 pharmaceutical companies through the national medical insurance catalog adjustment form review of the number of exclusive varieties.
(Photo source: Pharmaceutical Rubik's Cube) Among them, the number of drugs reviewed by Step Pharmaceuticals through the form of 7, Howson Pharmaceuticals, Peking University Pharmaceuticals, Hengrui Pharmaceuticals through the form of examination of the number of drugs up to 5, Guizhou Bailing, People's Fu Pharmaceuticals, Stone Pharmaceutical Group, Geopharmaceutical, Otsuka 5 pharmaceutical companies through the form of examination of the number of drugs for 4.
As for Kangyuan Pharmaceuticals, Ha Pharmaceuticals, Yiyi Pharmaceuticals, Lizhu Group, Baiji Shenzhou, Geli Pharmaceuticals, North China Pharmaceuticals, Synthesizer Pharmaceuticals, Kangchen Pharmaceuticals, Guilin Sanjin, Kangzhi Pharmaceuticals and other enterprises, although the number of exclusive varieties through formal review is relatively small, but also in 2.
the payment standard of medical insurance is also the focus of September 1st, the official implementation of the "Interim Measures for the Administration of Basic Medical Insurance Drug Use" clearly, the establishment of a perfect medical insurance catalog dynamic adjustment mechanism, in principle, the national medical insurance directory adjusted once a year.
, the list of declared drugs reviewed through the form included a total of 7 categories of drugs, of which individual drugs have a re-integration.
1: Drugs included in the New Coronavirus Pneumonia Diagnosis and Treatment Programme (Trial 7th Edition).
condition 2: Medicines included in the National Essential Medicines Directory (2018 edition).
Condition 3: To be included in the List of New Drugs In Clinically Urgent Need of Overseas Drugs (First Batch), List of New Drugs In Urgent Need of Overseas Medicines (Second Batch), List of First Batch of Encouraged Imitation Drugs, List of First Encouraging Research and Development of Declared Children's Drugs, or List of Third Batch of Children's Drugs For Encouraging Research and Development Declaration, and approved for listing by the State Drug Administration before August 17, 2020.
4: The second batch of state-organized drugs centralized procurement of the selected drugs.
5: From January 1, 2015 to August 17, 2020, a new generic drug was approved for sale by the State Drug Administration.
Condition 6: Between January 1, 2015 and August 17, 2020, according to the results of clinical trials, the State Drug Administration to supplement the application and obtain approval, adaptation, functional treatment and other significant changes in the drug.
conditions 7: By December 31, 2019, enter 5 (including) or more provincial-level the latest version of the basic medical insurance drug catalog of drugs.
, the main active ingredients are included in the "first batch of national key monitoring of rational drug use drug catalogue (chemical and biological products)" except.
note that the largest number of these varieties met the requirement of "entering the latest version of basic health insurance drugs at or above the provincial level by December 31, 2019", reaching 493.
In accordance with the relevant provisions of the medical insurance adjustment, the drugs reviewed and adopted will enter the expert evaluation stage (to fully take into account the distribution of pharmaceutical, pharmaceutical economy, management, clinical and other groups), after the expert review stage, will form a new transfer, direct transfer out, can be transferred out, adjust the limited payment scope and other four aspects of the drug recommendation list.
after a series of prescribed processes, the new version of the health care directory will be officially released, the new round of health insurance catalog is expected to be available by the end of the year.
in the process of adjusting the medical insurance catalog, the determination of the relevant drug medical insurance payment standards is the most concerned content in addition to the catalog access.
, in accordance with Article 12 of the Interim Measures for the Administration of Drug Use in Basic Medical Insurance, a mechanism for linking access to the Drug Catalog with the standards for the payment of medical insurance drugs shall be established.
addition to Chinese medicine tablets, in principle, the new drugs included in the "Drug Catalog" to determine the payment standards simultaneously.
exclusive drugs are negotiated through access to determine payment criteria.
non-exclusive drugs, the State organizes the centralized procurement of selected drugs and determines the payment standards in accordance with the relevant provisions of centralized procurement;
for the implementation of government-priced narcotic drugs and psycho-drugs in category I, the payment criteria are determined in accordance with government pricing.
must be said that with the publication of the new version of the health care directory, the relevant pharmaceutical companies in the end is happy or worried, we can only get the answer after the official directory published.
.